Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
PLoS ONE 11 (8), e0159573 (2016)
In people with fatty-liver disease (MASLD - metabolic dysfunction-associated steatotic liver disease), average liver fat fell by 82.4% at 24 weeks in the highest-dose group
Collectively, this review explores the emerging potential of integrating metabolic strategies into existing treatment regimens in the pursuit of improved outcomes for patients with this otherwise devastating malignancy
Aug 2019;25(2):74-82
An MJFF-funded Phase IIb placebo-controlled trial did show mild benefit but because the placebo group also improved, the significance of these results is unclear
US$ 23.94
US$ 29.08
US$ 27.20
US$ 24.96
